CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Rhythm Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Rhythm Pharmaceuticals Inc
222 Berkeley Street, 12th Floor Boston
Phone: (857) 264-4280p:857 264-4280 BOSTON, MA  02116  United States Ticker: RYTMRYTM
Business Summary
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS); or Bardet-Biedl syndrome (BBS). It is evaluating setmelanotide in Phase II and III trials for the treatment of obesity due to variants in one of numerous genes associated with the MC4R pathway.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer David P.Meeker 69 7/20/2020 11/1/2015
Chief Financial Officer, Treasurer Hunter C.Smith 56 3/1/2021 7/1/2017
Chief Human Resource Officer PamelaCramer 50 7/26/2021 7/26/2021
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Xinvento B.V. Brouwersgracht 187 H Amsterdam Netherlands

Business Names
Business Name
Rhythm Pharmaceuticals Canada Inc.
Rhythm Pharmaceuticals France SAS
Rhythm Pharmaceuticals Germany GmbH
9 additional Business Names available in full report.

General Information
Number of Employees: 226 (As of 2/1/2024)
Outstanding Shares: 61,457,069 (As of 11/3/2024)
Shareholders: 17
Stock Exchange: NASD
Federal Tax Id: 462159271
Fax Number: (857) 264-4299


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024